)
Visuals11 Sep 2026
TPL's revenue and FCF
Glycorex Transplantation
Glycorex Transplantation (GTAB) investor relations material
Glycorex Transplantation Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary28 Aug, 2026
Executive summary
Net sales for Q2 2026 were SEK 6.7 million, down 34% year-over-year, and SEK 15.4 million for H1 2026, down 22% year-over-year.
Operating income was SEK -4.2 million for Q2 and SEK -7.6 million for H1, reflecting a significant decline from the previous year.
Net income for Q2 was SEK -4.3 million and SEK -7.8 million for H1, with EPS at SEK -0.05 and SEK -0.10, respectively.
The decrease in sales is attributed to exceptionally strong sales in Mexico and Germany in 2025; several markets like Spain, Austria, Singapore, and India showed strong growth.
New CEO Carl-Magnus Schultz appointed in June 2026.
Financial highlights
Q2 net sales: SEK 6.7 million (Q2 2025: SEK 10.2 million); H1 net sales: SEK 15.4 million (H1 2025: SEK 19.8 million).
Q2 operating income: SEK -4.2 million (Q2 2025: SEK -1.0 million); H1 operating income: SEK -7.6 million (H1 2025: SEK -2.5 million).
Q2 net income: SEK -4.3 million (Q2 2025: SEK -1.1 million); H1 net income: SEK -7.8 million (H1 2025: SEK -2.8 million).
Cash and cash equivalents at period end: SEK 4.8 million (SEK 11.4 million in 2025).
Equity at period end: SEK 26.7 million (SEK 39.4 million in 2025); equity/assets ratio: 52.7% (74.8% in 2025).
Outlook and guidance
Focus on profitability and strategic improvements under new CEO.
Continued international expansion with new distribution agreements in Argentina and Malaysia.
Ongoing regulatory process for US market entry, especially for pediatric applications.
Growth expected in key markets such as Spain, Austria, Singapore, and India.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Glycorex Transplantation
- Improved sales and profitability in H1 2024, but negative cash flow and liquidity risks persist.GTAB
Q2 2024 - 10% sales growth, improved margins, and strategic wins drive positive momentum.GTABQ4 2025
- Q3 saw 29% sales growth, improved earnings, and strengthened liquidity via a SEK 10M share issue.GTABQ3 2025
- Sales volume up 8%, but net sales and earnings declined; cash flow remains negative.GTABQ1 2026
- Sales up 11% in Q2 2025, losses halved, and liquidity strengthened by new share issue.GTABQ2 2025
- Double-digit sales growth and improved results, with strategic expansion in key markets.GTABQ3 2024
- Strong sales growth and improved earnings, with expanded market presence and liquidity.GTABQ1 2025
- Double-digit sales growth and narrowed losses position Glycorex for global expansion.GTABQ4 2024
Next Glycorex Transplantation earnings date
Q3 202627 Nov, 2026
Glycorex Transplantation
Next Glycorex Transplantation earnings date
Q3 202627 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage